pediatric hematopoietic stem cell transplantation
Conditions
Sponsors
Children's Hospital of Shanghai
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for paients: 1. Aged 1 to 18 years; 2. Compliance with transplantation indications; 3. The guardian of the child has the desire and requirements for haploid hematopoietic stem cell transplantation, and sign the informed consent before treatment. The informed consent should inform all relevant contents of clinical research, and be willing to and abide by the treatment plan, follow-up plan, laboratory examination, etc. 4. Before transplantation, blood routine examination, liver and kidney function, complete set of virus, HLA antibody screening, ECG, cardiac ultrasound, lung function, lung CT and other examinations were completed before transplantation, and the contraindications of transplantation were excluded; 5. allo-HSCT was not received before this transplantation; 6. Agreed to assist third party cord blood transfusion. Screening criteria for cord blood: 1. cord blood banks in China inquired about suitable cord blood, expanded the screening scope to find more satisfactory cord blood; 2. eliminated DSA positive cord blood according to HLA antibody screening results; 3. HLA matching was the priority factor, and HLA >=4/6 loci (HLA-A, B, drbl serological matching) were consistent among donors and recipients; 4. the number of CD34 + in cord blood was more than 1x10^5/kg; 5. The optimal selection sequence of cord blood was HLA matching > CD34+ number > blood group > gender.
Exclusion criteria
Exclusion criteria: (1) There are any contraindications to hematopoietic stem cell transplantation. (2) There are other serious diseases, such as serious damage of vital organs, respiratory failure, heart failure, liver insufficiency and renal insufficiency in decompensated period. (3) Other clinical researchers are in progress. (4) At the same time, suffering from other severe acute or chronic physiological or mental diseases, or abnormal laboratory examination, which may affect the patient's life safety and compliance, affect informed consent, research participation, follow-up or result interpretation. (5) They do not agree to assist the third-party cord blood transfusion or fail to screen qualified cord blood that meets the screening criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hematopoietic reconstitution;Immune reconstitution; | — |
Secondary
| Measure | Time frame |
|---|---|
| complication;survival rate; | — |
Countries
China
Contacts
Public ContactKai Chen
Children's Hospital of Shanghai
Outcome results
None listed